Convatec Group (CTEC) Fair Value & Analysis
Healthcare · GB · Market cap 3.8B GBX
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 6 days ago
Share price +6.3% over the past month.
Price vs Fair Value (12 months)
12‑month range £1.87 – £2.56 · fair‑value band £1.17 – £2.81 · the £2.07 price screens above the £2.01 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Convatec Group (CTEC) currently trades at £2.07, while our model-based Fair Value estimate is £2.01 — implying the stock looks roughly 2.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Convatec Group generated revenue of £2.4B at a net margin of 7.2%. Revenue grew 7.1% year over year. It earns a return on equity of 10.9%. Net debt stands at £1.5B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such a…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Convatec Group reported revenue of £2.5B in FY2025 versus £2.0B in FY2021, a compound +5.1%/yr. Reported net income was £179M in FY2025, compounding +11.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $143.92 | $104.17 | -28% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Convatec Group (CTEC) undervalued?
What is the fair value of CTEC?
What is the quality score of CTEC?
What is the revenue of Convatec Group (CTEC)?
What is the net profit margin of CTEC?
Does Convatec Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.